The discovery of targetable genetic alterations, such as activating mutations of the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) rearrangements, has led to the implementation of precision therapy for certain subtypes of lung cancer based on appropriate patient selection [9]. Here, ALK is linked to lung carcinoma.